Bluejay Diagnostics, Inc.
BJDX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.04 | 0.00 |
| FCF Yield | -86.09% | -198.25% | -222.97% | -189.85% |
| EV / EBITDA | 0.99 | 1.27 | 2.14 | 3.63 |
| Quality | ||||
| ROIC | -36.32% | -46.51% | -24.91% | -18.36% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 1.05 | 0.64 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -73.36% | 31.90% | 9.93% | -3.93% |
| Safety | ||||
| Net Debt / EBITDA | 2.23 | 1.59 | 2.65 | 4.45 |
| Interest Coverage | -8,943.07 | 0.00 | -2,036.55 | -7.14 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -255.34 | -901.03 | -114.82 | -531.97 |